<DOC>
	<DOCNO>NCT02760992</DOCNO>
	<brief_summary>The purpose study identify suitable dose regimen IV baclofen serve temporary substitute oral regimen .</brief_summary>
	<brief_title>Repeated Dose IV Baclofen Safety/Bioequivalence Study</brief_title>
	<detailed_description>Baclofen intravenous solution 2 mg/mL manufacture provided Allaysis , LLC . Prism Clinical Research purchase oral baclofen tablet ( 10 mg ) commercial supplier . Subject start baclofen 5 mg oral dose every 8 hour . Oral baclofen increase incrementally self-administered 13 day maximum dose 20 mg every 8 hour . Subjects cross 16 mg intravenous baclofen infuse 120 ( n=6 ) 150 ( n=6 ) minute every 8 hour 11 dos . Subjects change back oral baclofen 15 mg dose self-administered every 8 hour taper baclofen 15 day . Following completion group 12 subject , remain 30 subject receive IV baclofen infusion duration best meet criteria bioequivalence .</detailed_description>
	<criteria>Males female age 1845 . An attempt make recruit equal number men woman dose group ; however ratio 2:4 initial runin phase 12:18 , either woman men majority acceptable . Subjects capable give informed consent . Females capable bearing child practice least one follow method contraception least one month prior study : hormonal , intrauterine device ( IUD ) , barrier method combination spermicide . Female subject postmenopausal ( menses great one year ) surgically incapable bear child may participate . Subject medication free , hormonal birth control , 48 hour 24 hour completion study drug administration . If need medication identify time period , discuss approve PI . Women pregnant . Women breastfeed . Subject history intolerance IV administration medication . Subject know hypersensitivity baclofen . Subject significant history cardiac , neurologic , psychiatric , oncologic , endocrine , metabolic , renal hepatic disease Subject take used investigational drug device 30 day prior screen . Subject take either prescribed counter medication , hormonal birth control within 48 hour prior baclofen administration , unless approve Principal Investigator . Subject reveals clinically significant abnormality screen laboratory test . Subject nonEnglish speaker , ability ascertain neurological status would require interpreter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>